Tag: dupilumab
Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms
Infants and young children finally get relief from eczema’s terrible itch
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...
Majority of patients achieved histological disease remission in 16 weeks.
FDA Approves First Treatment for Eosinophilic Esophagitis (EoE), a Chronic Immune...
EoE is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in the tissue of the esophagus.
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12...
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis.
CHOP Receives $2M Philanthropic Gift to Launch Food Allergy Study Using...
"A successful clinical trial would open the possibility of food introduction to more than 3,500 CHOP patients with EoE."
Dupixent (dupilumab) Study Shows Significant Improvement in Eosinophilic Esophagitis Signs and...
Phase 3 trial in (EoE) to show a significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Study scheduled to commence next week.
